ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · IEX Real-Time Price · USD
0.826
-0.054 (-6.19%)
At close: Jul 19, 2024, 4:00 PM
0.819
-0.007 (-0.84%)
Pre-market: Jul 22, 2024, 9:00 AM EDT
ABVC BioPharma Employees
As of December 31, 2023, ABVC BioPharma had 19 total employees, including 16 full-time and 3 part-time employees. The number of employees decreased by 4 or -17.39% compared to the previous year.
Employees
19
Change (1Y)
-4
Growth (1Y)
-17.39%
Revenue / Employee
$1,335
Profits / Employee
-$664,470
Market Cap
9.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
PAVmed | 107 |
Tonix Pharmaceuticals Holding | 103 |
Pieris Pharmaceuticals | 50 |
Plus Therapeutics | 20 |
Traws Pharma | 18 |
Moleculin Biotech | 18 |
Elevai Labs | 18 |
Inhibikase Therapeutics | 9 |
ABVC News
- 3 months ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 3 months ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 3 months ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 4 months ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 4 months ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire
- 4 months ago - ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - GlobeNewsWire
- 5 months ago - ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues - GlobeNewsWire
- 5 months ago - ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) - GlobeNewsWire